Therapeutic options for metastatic breast cancer

Patrick G. Morris; Heather L. McArthur; Clifford A. Hudis

doi:10.1517/14656560902834961

Therapeutic options for metastatic breast cancer

Patrick G. Morris, Heather L. McArthur, Clifford A. Hudis

Research output: Contribution to journal › Review article › peer-review

47 Scopus citations

Abstract

Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.

Original language	English (US)
Pages (from-to)	967-981
Number of pages	15
Journal	Expert Opinion on Pharmacotherapy
Volume	10
Issue number	6
DOIs	https://doi.org/10.1517/14656560902834961
State	Published - Apr 2009
Externally published	Yes

Keywords

Breast cancer
Chemotherapy
Endocrine therapy
Metastatic disease
Targeted agents

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/14656560902834961

Cite this

@article{8d7e0f98136c418e99817d5a5d50c880,

title = "Therapeutic options for metastatic breast cancer",

abstract = "Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.",

keywords = "Breast cancer, Chemotherapy, Endocrine therapy, Metastatic disease, Targeted agents",

author = "Morris, {Patrick G.} and McArthur, {Heather L.} and Hudis, {Clifford A.}",

year = "2009",

month = apr,

doi = "10.1517/14656560902834961",

language = "English (US)",

volume = "10",

pages = "967--981",

journal = "Expert Opinion on Pharmacotherapy",

issn = "1465-6566",

publisher = "Informa Healthcare",

number = "6",

}

TY - JOUR

T1 - Therapeutic options for metastatic breast cancer

AU - Morris, Patrick G.

AU - McArthur, Heather L.

AU - Hudis, Clifford A.

PY - 2009/4

Y1 - 2009/4

N2 - Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.

AB - Metastatic breast cancer (MBC) remains an incurable disease despite ongoing therapeutic advances. Recently there has been progress extending the range of available cytotoxic chemotherapy drugs and optimizing their scheduling. In addition, a greater understanding of tumor biology has led to the development of a number of targeted therapies. Several of these newer agents, such as trastuzumab, lapatinib and bevacizumab, have demonstrated activity in combination with chemotherapy and have improved the prognosis of patients with MBC. We hope that further progress elucidating the pathophysiology and biology of MBC will continue to lead to corresponding advances in treatment.

KW - Breast cancer

KW - Chemotherapy

KW - Endocrine therapy

KW - Metastatic disease

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=67649592084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649592084&partnerID=8YFLogxK

U2 - 10.1517/14656560902834961

DO - 10.1517/14656560902834961

M3 - Review article

C2 - 19351274

AN - SCOPUS:67649592084

SN - 1465-6566

VL - 10

SP - 967

EP - 981

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

IS - 6

ER -

Therapeutic options for metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this